Incyte Corp. buy marge
Start price
18.09.17
/
50%
€107.19
Target price
04.11.21
€135.30
Performance (%)
-45.48%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. Massive losses of -45.48% were the result for the BUY prediction by marge. marge has a follow-up prediction for Incyte Corp. where he still thinks Incyte Corp. is a Buy. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | -2.417% | -2.417% | 27.465% | 13.141% |
| iShares Core DAX® | 0.224% | 2.457% | 21.634% | 71.886% |
| iShares Nasdaq 100 | 0.371% | -0.320% | 5.422% | 113.046% |
| iShares Nikkei 225® | 0.972% | -0.829% | 15.333% | 47.267% |
| iShares S&P 500 | 0.417% | -0.157% | 3.125% | 68.687% |
Comments by marge for this prediction
In the thread Incyte Corp. diskutieren
marge stimmt der Buy-Einschätzung von datca zu: siehe Beschreibung
marge stimmt am 17.11.2016 der Buy-Einschätzung von datca mit dem Kursziel 120$ zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
In the thread Trading Incyte Corp.
Die von marge gewählte maximale Laufzeit wurde überschritten